Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index; 46 of the 149 sources its claims cite were checked for support.

Triple Agonism Based Therapies for Obesity

Open access

Abstract

Purpose of the Review: Glucagon-like peptide 1 (GLP-1) receptor agonists (RA) have transformed obesity and type 2 diabetes (T2D) management. Tirzepatide, the first dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) RA approved for both conditions, has paved the way for next-generation incretin-based therapies. Among these, triple agonists targeting GLP-1, GIP, and glucagon receptors represent a promising next step. This review outlines the rationale for their development and summarizes clinical trial data, focusing on retatrutide, the most advanced candidate. Recent Findings: Retatrutide is the first triple agonist (acting on GLP-1/GIP/glucagon receptors) with published phase 2 data in people with obesity as well as in people with T2D. Retatrutide achieved up to 24.2% mean weight loss after 48 weeks in individuals with obesity and 16.9% in those with T2D after 36 weeks. In the T2D study, HbA1c improved by 2.2%, with 82% of participants reaching HbA1c ≤ 6.5%. Retatrutide also improved multiple cardiometabolic parameters, including blood pressure, lipids, waist circumference, and liver fat (82% reduction in hepatic steatosis). Gastrointestinal symptoms were the most common side effects; no major safety concerns were observed. A comprehensive phase 3 program is ongoing to evaluate efficacy, safety, and cardiovascular/renal outcomes in people with obesity and/or T2D. Other unimolecular triple agonists and combination regimens involving tirzepatide with additional mono agonists are also in development. Summary: Retatrutide, a triple agonist now in phase 3 trials, has the potential to become the most effective pharmacological treatment for obesity while also offering substantial benefits in T2D management and other cardiometabolic risk factors.

Overview

CoChat Summary

## TL;DR

This review argues that triple agonists targeting GLP-1/GIP/glucagon receptors are the next major step beyond tirzepatide for obesity and type 2 diabetes, with retatrutide the leading candidate. Phase 2 data reported up to 24.2% mean weight loss at 48 weeks in obesity and 16.9% at 36 weeks in type 2 diabetes, with generally GI-limited adverse effects and no major safety signal.

## Key findings

  • In the obesity phase 2 trial, retatrutide 12 mg produced 24.2% mean weight loss at 48 weeks vs 2.1% with placebo; 64% vs 1% achieved ≥20% weight loss.
  • In the type 2 diabetes phase 2 trial, retatrutide 12 mg produced 16.9% weight loss at 36 weeks vs 3.0% with placebo and 2.0% with dulaglutide 1.5 mg.
  • In the type 2 diabetes trial, retatrutide 12 mg reduced HbA1c by 2.16% at 36 weeks; 77–82% of participants on retatrutide 8–12 mg achieved HbA1c ≤ 6.5%.
  • Retatrutide improved other cardiometabolic outcomes, including waist circumference, lipids, blood pressure, and in a liver-fat substudy, hepatic steatosis fell by 82.4% with 12 mg at 24 weeks; 86% achieved healthy liver fat levels (<5%).
  • The paper reports that adverse effects were mainly mild-to-moderate gastrointestinal symptoms; serious adverse events in phase 2 were 4% overall in the obesity trial and 4–8% across retatrutide arms in the type 2 diabetes trial.

## Methods

  • Narrative review of completed and ongoing clinical trials of triple agonists for obesity, with emphasis on retatrutide as the most advanced agent.
  • Summarizes phase 1, phase 1b, and two published phase 2 trials: one in 338 participants with obesity without T2D and one in 281 participants with T2D and overweight/obesity.
  • Main analysis is descriptive synthesis of trial designs and outcomes, including weight loss, glycaemia, cardiometabolic markers, liver fat, kidney markers, and adverse events.

## Limitations

  • The paper states that long-term safety, efficacy, and cardiovascular/renal outcomes are still awaited, and that cardiovascular outcome trials for multi-agonists have not yet been completed.
  • The text makes evident that evidence is still early-stage and largely from phase 2 trials; this is an implication from the paper’s own framing of retatrutide as the lead candidate with ongoing phase 3 studies.
  • The paper notes that head-to-head trials versus currently approved obesity treatments do not exist; this limits direct comparative conclusions.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1007/s12170-025-00770-z

Cites

66 of 66 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Demonstrated metabolic effects of GIP, GLP-1 and GCG agonism as mono, dual and triple receptor agonists. Arrows represent effects as compared to no treatment/ placebo unless otherwise stated. *Data shown relate to long-acting GIP RA use only. **Decreased emesis as compared to GLP-1RA use alone. GIP: Glucose-dependent insulinotropic polypeptide; GLP-1: Glucagon-like peptide 1; GCG: Glucagon; RA: Receptor agonist
Fig. 1 Demonstrated metabolic effects of GIP, GLP-1 and GCG agonism as mono, dual and triple receptor agonists. Arrows represent effects as compared to no treatment/ placebo unless otherwise stated. *Data shown relate to long-acting GIP RA use only. **Decreased emesis as compared to GLP-1RA use alone. GIP: Glucose-dependent insulinotropic polypeptide; GLP-1: Glucagon-like peptide 1; GCG: Glucagon; RA: Receptor agonistCC BY · PubMed Central
Fig. 2 The pipeline of phase 2 and phase 3 trials investigating the efficacy and safety of retatrutide. T2D: Type 2 diabetes; SGLT-2: Sodium-glucose co-transporter-2; OA: Osteoarthritis; OSA: Obstructive sleep apnoea; WOMAC: Western Ontario and McMaster Universities Osteoarthritis Index; AHI: Apnoea-Hypopnea Index; MTD: Maximum tolerated dose; ESKD: End-stage kidney disease; eGFR: estimated glomerular filtration rate; CV: Cardiovascular; CVD: Cardiovascular disease; ASCVD: Atherosclerotic cardiovascular disease; BMI: Body mass index; MI: Myocardial infarction; CKD: Chronic kidney disease.
Fig. 2 The pipeline of phase 2 and phase 3 trials investigating the efficacy and safety of retatrutide. T2D: Type 2 diabetes; SGLT-2: Sodium-glucose co-transporter-2; OA: Osteoarthritis; OSA: Obstructive sleep apnoea; WOMAC: Western Ontario and McMaster Universities Osteoarthritis Index; AHI: Apnoea-Hypopnea Index; MTD: Maximum tolerated dose; ESKD: End-stage kidney disease; eGFR: estimated glomerular filtration rate; CV: Cardiovascular; CVD: Cardiovascular disease; ASCVD: Atherosclerotic cardiovascular disease; BMI: Body mass index; MI: Myocardial infarction; CKD: Chronic kidney disease.CC BY · PubMed Central
Fig. 3 Weight loss with retatrutide as compared to currently licenced obesity pharmacotherapy. Data from: [8, 27, 45, 49, 46, 50]
Fig. 3 Weight loss with retatrutide as compared to currently licenced obesity pharmacotherapy. Data from: [8, 27, 45, 49, 46, 50]CC BY · PubMed Central
Fig. 4 Weight loss with retatrutide as compared to licenced obesity pharmacotherapies and upcoming dual agonists in phase 3 trials in people with obesity and with type 2 diabetes. GIP: Glucose-dependent insulinotropic polypeptide; GLP-1: Glucagon-like peptide 1; GCG: Glucagon; RA: Receptor agonist; qw: once weekly dosing; biw: twice weekly dosing. Data from: [45, 50, 27, 8, 46, 49, 51, 35, 52, 36, 53]
Fig. 4 Weight loss with retatrutide as compared to licenced obesity pharmacotherapies and upcoming dual agonists in phase 3 trials in people with obesity and with type 2 diabetes. GIP: Glucose-dependent insulinotropic polypeptide; GLP-1: Glucagon-like peptide 1; GCG: Glucagon; RA: Receptor agonist; qw: once weekly dosing; biw: twice weekly dosing. Data from: [45, 50, 27, 8, 46, 49, 51, 35, 52, 36, 53]CC BY · PubMed Central

Verification

Claims the paper makes

35 Valid · 1 Not valid · 65 Not checked · 7 Own results and interpretations

55 more claims · 11 with their cited sources checked

Create a free account to see all 108 claims and every source verdict.

See all claims — free account
  • Probably not a substantial claim. 9
  • It may state two separate claims as one. 42
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Citations

Cites

Show all 66 references

Cited by

See all 22

Metadata

Authors
Goldney, J., Hamza, M., Surti, F., Davies, M. J., & Papamargaritis, D.
Affiliations
University of Leicester (GB)
Corresponding author
Papamargaritis, Dimitris
Venue
Current Cardiovascular Risk Reports
Published
2025-07-28
Volume
19
Issue
1
Pages
18-18
ISSN
  • 1932-9520 (ISSN-L)
  • 1932-9563
OpenAlex
W4412684430
Cited by
22
References
66
Citations by year
2026: 20 · 2025: 2
FWCI
2.97
Type
journal article
Language
en
Open access
Licence
Locations
  • Current Cardiovascular Risk Reports (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Figshare (submittedVersion, cc-by)
Funders
  • Wellcome Trust Leicestershire Healthcare Inequalities Improvement Doctoral Training Programme (223512/Z/21/Z)
  • NIHR Leicester Biomedical Research Centre
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
Keywords
obesity, type 2 diabetes, retatrutide, GLP-1 receptor agonists, GIP receptor agonist, glucagon receptor agonist, incretin-based therapy, weight loss, glycemic control, hepatic steatosis, cardiometabolic risk, gastrointestinal adverse effects

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Triple Agonism Based Therapies for Obesity. https://app.cochat.ai/papers/10.1007/s12170-025-00770-z
The paper
Goldney, J., Hamza, M., Surti, F., Davies, M. J., & Papamargaritis, D. (2025). Triple Agonism Based Therapies for Obesity. Current Cardiovascular Risk Reports. https://doi.org/10.1007/s12170-025-00770-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.